A sofosbuvir-based direct-acting antiviral treatment regimen exhibits a strong protective effect against post-liver transplantation chronic hepatitis C recurrence

Atsushi Oyama; Akinobu Takaki; Tetsuya Yasunaka; Takuya Adachi; Fusao Ikeda; Nozomu Wada; Yasuhito Takeuchi; Hideki Onishi; Shinichiro Nakamura; Hidenori Shiraha; Kosei Takagi; Takashi Kuise; Daisuke Nobuoka; Ryuichi Yoshida; Yuzo Umeda; Mari Yoshida; Chisato Arimori; Takahito Yagi; Hiroyuki Okada

doi:10.2957/kanzo.58.599

A sofosbuvir-based direct-acting antiviral treatment regimen exhibits a strong protective effect against post-liver transplantation chronic hepatitis C recurrence

Atsushi Oyama, Akinobu Takaki, Tetsuya Yasunaka, Takuya Adachi, Fusao Ikeda, Nozomu Wada, Yasuhito Takeuchi, Hideki Onishi, Shinichiro Nakamura, Hidenori Shiraha, Kosei Takagi, Takashi Kuise, Daisuke Nobuoka, Ryuichi Yoshida, Yuzo Umeda, Mari Yoshida, Chisato Arimori, Takahito Yagi, Hiroyuki Okada

Research output: Contribution to journal › Article › peer-review

Abstract

The efficacy and safety of anti-hepatitis C virus (HCV. direct-acting antivirals were evaluated in postorthotopic liver transplantation patients. There were 29 patients with HCV genotype 1 and 2 with genotype 2. Of the 29 genotype 1 patients, 5 received daclatasvir (DCV. + asunaprevir (ASV), and 25 received sofosbuvir (SOF. + ledipasvir (LDV), including 1 who had failed DCV + ASV. Both genotype 2 patients received SOF + ribavirin. Four patients with DCV + ASV completed the protocol, and 3 of them achieved a sustained viral re-sponse for 24 weeks (SVR24). All of the patients who received SOF + LDV and SOF + RBV achieved SVR24 with minor adverse events. In post-liver transplantation patients, SOF-based regimens showed highly satisfactory efficacy and safety.

Original language	English
Pages (from-to)	599-604
Number of pages	6
Journal	Acta Hepatologica Japonica
Volume	58
Issue number	11
DOIs	https://doi.org/10.2957/kanzo.58.599
Publication status	Published - 2017

Keywords

Chronic hepatitis C
Direct acting antivirals (DAA)
Interferon free
Liver transplantation
Transplantation immunity

ASJC Scopus subject areas

Hepatology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2957/kanzo.58.599

Cite this

Oyama, A., Takaki, A., Yasunaka, T., Adachi, T., Ikeda, F., Wada, N., Takeuchi, Y., Onishi, H., Nakamura, S., Shiraha, H., Takagi, K., Kuise, T., Nobuoka, D., Yoshida, R., Umeda, Y., Yoshida, M., Arimori, C., Yagi, T., & Okada, H. (2017). A sofosbuvir-based direct-acting antiviral treatment regimen exhibits a strong protective effect against post-liver transplantation chronic hepatitis C recurrence. Acta Hepatologica Japonica, 58(11), 599-604. https://doi.org/10.2957/kanzo.58.599

Oyama, A, Takaki, A, Yasunaka, T, Adachi, T, Ikeda, F, Wada, N, Takeuchi, Y, Onishi, H, Nakamura, S, Shiraha, H , Takagi, K, Kuise, T, Nobuoka, D, Yoshida, R , Umeda, Y, Yoshida, M, Arimori, C, Yagi, T & Okada, H 2017, 'A sofosbuvir-based direct-acting antiviral treatment regimen exhibits a strong protective effect against post-liver transplantation chronic hepatitis C recurrence', Acta Hepatologica Japonica, vol. 58, no. 11, pp. 599-604. https://doi.org/10.2957/kanzo.58.599

@article{52d19e1ed2b746ab88cc3e7faf691f2c,

title = "A sofosbuvir-based direct-acting antiviral treatment regimen exhibits a strong protective effect against post-liver transplantation chronic hepatitis C recurrence",

abstract = "The efficacy and safety of anti-hepatitis C virus (HCV. direct-acting antivirals were evaluated in postorthotopic liver transplantation patients. There were 29 patients with HCV genotype 1 and 2 with genotype 2. Of the 29 genotype 1 patients, 5 received daclatasvir (DCV. + asunaprevir (ASV), and 25 received sofosbuvir (SOF. + ledipasvir (LDV), including 1 who had failed DCV + ASV. Both genotype 2 patients received SOF + ribavirin. Four patients with DCV + ASV completed the protocol, and 3 of them achieved a sustained viral re-sponse for 24 weeks (SVR24). All of the patients who received SOF + LDV and SOF + RBV achieved SVR24 with minor adverse events. In post-liver transplantation patients, SOF-based regimens showed highly satisfactory efficacy and safety.",

keywords = "Chronic hepatitis C, Direct acting antivirals (DAA), Interferon free, Liver transplantation, Transplantation immunity",

author = "Atsushi Oyama and Akinobu Takaki and Tetsuya Yasunaka and Takuya Adachi and Fusao Ikeda and Nozomu Wada and Yasuhito Takeuchi and Hideki Onishi and Shinichiro Nakamura and Hidenori Shiraha and Kosei Takagi and Takashi Kuise and Daisuke Nobuoka and Ryuichi Yoshida and Yuzo Umeda and Mari Yoshida and Chisato Arimori and Takahito Yagi and Hiroyuki Okada",

year = "2017",

doi = "10.2957/kanzo.58.599",

language = "English",

volume = "58",

pages = "599--604",

journal = "Acta Hepatologica Japonica",

issn = "0451-4203",

publisher = "Japan Society of Hepatology",

number = "11",

}

TY - JOUR

T1 - A sofosbuvir-based direct-acting antiviral treatment regimen exhibits a strong protective effect against post-liver transplantation chronic hepatitis C recurrence

AU - Oyama, Atsushi

AU - Takaki, Akinobu

AU - Yasunaka, Tetsuya

AU - Adachi, Takuya

AU - Ikeda, Fusao

AU - Wada, Nozomu

AU - Takeuchi, Yasuhito

AU - Onishi, Hideki

AU - Nakamura, Shinichiro

AU - Shiraha, Hidenori

AU - Takagi, Kosei

AU - Kuise, Takashi

AU - Nobuoka, Daisuke

AU - Yoshida, Ryuichi

AU - Umeda, Yuzo

AU - Yoshida, Mari

AU - Arimori, Chisato

AU - Yagi, Takahito

AU - Okada, Hiroyuki

PY - 2017

Y1 - 2017

N2 - The efficacy and safety of anti-hepatitis C virus (HCV. direct-acting antivirals were evaluated in postorthotopic liver transplantation patients. There were 29 patients with HCV genotype 1 and 2 with genotype 2. Of the 29 genotype 1 patients, 5 received daclatasvir (DCV. + asunaprevir (ASV), and 25 received sofosbuvir (SOF. + ledipasvir (LDV), including 1 who had failed DCV + ASV. Both genotype 2 patients received SOF + ribavirin. Four patients with DCV + ASV completed the protocol, and 3 of them achieved a sustained viral re-sponse for 24 weeks (SVR24). All of the patients who received SOF + LDV and SOF + RBV achieved SVR24 with minor adverse events. In post-liver transplantation patients, SOF-based regimens showed highly satisfactory efficacy and safety.

AB - The efficacy and safety of anti-hepatitis C virus (HCV. direct-acting antivirals were evaluated in postorthotopic liver transplantation patients. There were 29 patients with HCV genotype 1 and 2 with genotype 2. Of the 29 genotype 1 patients, 5 received daclatasvir (DCV. + asunaprevir (ASV), and 25 received sofosbuvir (SOF. + ledipasvir (LDV), including 1 who had failed DCV + ASV. Both genotype 2 patients received SOF + ribavirin. Four patients with DCV + ASV completed the protocol, and 3 of them achieved a sustained viral re-sponse for 24 weeks (SVR24). All of the patients who received SOF + LDV and SOF + RBV achieved SVR24 with minor adverse events. In post-liver transplantation patients, SOF-based regimens showed highly satisfactory efficacy and safety.

KW - Chronic hepatitis C

KW - Direct acting antivirals (DAA)

KW - Interferon free

KW - Liver transplantation

KW - Transplantation immunity

UR - http://www.scopus.com/inward/record.url?scp=85037361985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037361985&partnerID=8YFLogxK

U2 - 10.2957/kanzo.58.599

DO - 10.2957/kanzo.58.599

M3 - Article

AN - SCOPUS:85037361985

SN - 0451-4203

VL - 58

SP - 599

EP - 604

JO - Acta Hepatologica Japonica

JF - Acta Hepatologica Japonica

IS - 11

ER -

A sofosbuvir-based direct-acting antiviral treatment regimen exhibits a strong protective effect against post-liver transplantation chronic hepatitis C recurrence

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this